

## COMPANY OVERVIEW

VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen's three drug candidates, PH94B, PH10, and AV-101, has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets.

## RECENT NEWS

### Nasdaq Grants VistaGen 180-Day Extension to Meet Minimum Bid Price Requirement

Oct 14 2020, 8:30 AM EDT

## STOCK OVERVIEW

Symbol	VTGN
Exchange	Nasdaq
Market Cap	60.68m
Last Price	\$0.82
52-Week Range	\$0.2943 - \$1.4862

10/20/2020 04:00 PM EDT

## INVESTOR RELATIONS

**VistaGen Therapeutics, Inc.**  
Mark A. McPartland  
Vice President, Corporate Development  
and Investor Relations  
(650) 577-3606  
[markmcp@vistagen.com](mailto:markmcp@vistagen.com)

## MANAGEMENT TEAM

**Shawn K. Singh, J.D.**  
Chief Executive Officer and Director

**H. Ralph Snodgrass, Ph.D.**  
Founder, President, Chief Scientific Officer  
and Director

**Mark A. Smith, M.D., Ph.D.**  
Chief Medical Officer

**Jerrold D. Dotson, CPA**  
Vice President, Chief Financial Officer and  
Secretary

**Mark A. McPartland**  
Vice President of Corporate Development

## VISTAGEN THERAPEUTICS, INC.

343 Allerton Avenue  
South San Francisco, CA 94080

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.